Series A Round Valuation: ¥9 Billion: MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors
Rhea-AI Summary
MEDIROM MOTHER Labs (NASDAQ: MRM) approved a private placement of new shares to two officers at a Series A valuation of ¥9 billion, with funding scheduled by the end of October 2025. The capital increase is led by management investors Yoshio Uekusa and Ryo Saito to strengthen rapid decision-making and field-rooted management.
The funding will bolster the capital base and support development of an upgraded MOTHER Bracelet wearable and systems for product commercialization, while advancing domestic and international business expansion in healthcare and wellness.
Positive
- Series A valuation set at ¥9 billion
- Private placement scheduled to close by end of October 2025
- Management investment by CEO and Director to align incentives
- Funding earmarked for upgraded MOTHER Bracelet development and commercialization
Negative
- None.
Insights
Management-led Series A values MOTHER Labs at
The capital increase converts management into equity holders, directly strengthening MOTHER Labs’s capital base and aligning leadership incentives with execution on the upgraded MOTHER Bracelet and market rollout. The move funds product development and commercialization systems while keeping control within existing leadership, which preserves strategic continuity.
Key dependencies include timely receipt of the funding by the end of
TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), today announced that it has approved a private placement of new shares to two officers, Yoshio Uekusa, President and CEO, and Ryo Saito, Director, as part of its Series A financing round, at a valuation of JPY9 billion. Funding is scheduled to occur by the end of October.
◼︎Background for Implementation
MOTHER Labs serves as the health tech division within the MEDIROM Group, having previously implemented specific health guidance programs using the healthcare app “Lav” and promoted the development and sales of wearable devices. To accelerate further business expansion, we determined that strengthening rapid decision-making and a management structure rooted in the field is essential. Therefore, it was decided to conduct this capital increase with the management team itself becoming investors, aiming to further heighten business responsibility and growth motivation.
◼︎Future Outlook
Through this capital increase, MOTHER Labs will strengthen its capital base while advancing the development of an upgraded version of its wearable device, the MOTHER Bracelet, and establishing systems for bringing products to market.
As the MEDIROM Group, we will realize new value creation in the healthcare and wellness field and further drive business growth both domestically and internationally.
MEDIROM MOTHER Labs Inc.
President and CEO
Yoshio Uekusa
March 2014: Graduated from Keio University, Faculty of Economics
April 2014: Joined Riraku Co., Ltd. (now MEDIROM Co., Ltd.)
January 2017: CEO Assistant and New Graduate Recruitment Team, MEDIROM Healthcare Technologies Inc.
June 2019: General Manager, Recruitment Group, MEDIROM Healthcare Technologies Inc.
June 2022: General Manager, MOTHER Group, MEDIROM Healthcare Technologies Inc.
July 2023: Representative Director, MEDIROM MOTHER Labs Co., Ltd. (Current Position)
MEDIROM MOTHER Labs Inc.
Director
Ryo Saito
March 2014: Graduated from Hokkai Gakuen University, Faculty of Business Administration
April 2014: Joined Riraku Co., Ltd. (now MEDIROM Co., Ltd.)
January 2017: Appointed Manager, Operations Group
November 2018: Appointed General Manager, Product Development Group
July 2020: Appointed General Manager, Development Group
July 2021: Appointed Director, Joy Hands Wellness Co., Ltd.
July 2024: Transferred to MOTHER Group
June 2025: Appointed Director, MEDIROM MOTHER Labs Co., Ltd. (current position)
■ABOUT MEDIROM MOTHER Labs Inc.
A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health- tech sector. The company’s core activities include the 'Specific Health Guidance Program' offered through the 'Lav' health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.
◼︎MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web: https://medirom.co.jp/en
■Forward-Looking Statements Regarding MEDIROM
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:
● MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;
● changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;
● MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;
● the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;
● MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;
● MEDIROM’s ability to raise additional capital on acceptable terms or at all;
● MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;
● changes in consumer preferences and MEDIROM’s competitive environment;
● MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and
● the regulatory environment in which MEDIROM operates.
More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact:
ir@medirom.co.jp
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e7479d19-28e0-4134-83b2-15eb647422a9
https://www.globenewswire.com/NewsRoom/AttachmentNg/8c5cb1b1-22a1-40e2-a14a-92fedc6e9e39
https://www.globenewswire.com/NewsRoom/AttachmentNg/59af2fa5-8de8-42d4-8f1f-741522527198
https://www.globenewswire.com/NewsRoom/AttachmentNg/81e69d32-490c-496c-9abc-1a62330e27e1
FAQ
What did MEDIROM MOTHER Labs announce on October 9, 2025 (MRM)?
Who are the investors participating in MOTHER Labs' Series A private placement (MRM)?
How will the Series A funds be used by MEDIROM MOTHER Labs (MRM)?
When is the Series A funding for MEDIROM MOTHER Labs expected to close (MRM)?
What does management investing in MOTHER Labs mean for shareholders of MEDIROM (MRM)?
